Zymeworks to Share Insights at Key Investor Conferences

Insights into Zymeworks' Upcoming Investor Conferences

Zymeworks Inc. (NASDAQ: ZYME) is poised to make significant waves in the biotechnology field as it announces its participation in various upcoming investor conferences aimed at showcasing its innovative approach to treating difficult-to-manage diseases. As a clinical-stage biotechnology company, Zymeworks is deeply committed to developing a diverse array of novel and multifunctional biotherapeutics.

Major Conferences Zymeworks Will Attend

Management at Zymeworks will participate in several noteworthy investor conferences, providing attendees with valuable insights into the company's research and strategies:

Piper Sandler Healthcare Conference

On December 3, Zymeworks' management team plans to engage in one-on-one meetings and present at the Piper Sandler 36th Annual Healthcare Conference. The presentation is scheduled for 1:30 PM Eastern Time in New York.

Citi's 2024 Global Healthcare Conference

Also on December 3, Zymeworks will take part in Citi's 2024 Global Healthcare Conference. The management team will engage in one-on-one meetings and participate in a panel discussion exploring 'Novel Antibody Mechanisms in Oncology' at 3:15 PM ET in Miami.

Evercore HealthCONx Conference

Following these key events, the management will attend the 7th Annual Evercore HealthCONx Conference on December 4, where they will continue to have one-on-one meetings and will engage in a fireside chat at 7:55 AM ET in Coral Gables.

Annual J.P. Morgan Healthcare Conference

Looking ahead to January 13-16, 2025, Zymeworks will participate in the 43rd Annual J.P. Morgan Healthcare Conference. During this event, it will hold one-on-one meetings and a corporate presentation on January 16 at 8:15 AM Pacific Time in San Francisco.

Research & Development Day and Future Innovations

In addition to participation in investor conferences, Zymeworks is set to present updates on its preclinical research programs at the upcoming Research & Development Day. This event will occur virtually and in-person on December 12, 2024, also in New York. Dr. Paul Moore, Zymeworks' Chief Scientific Officer, will lead the session.

What to Expect at the Research Event

The Research & Development Day will include:

• Recent developments in Zymeworks' solid tumor-targeting antibody-drug conjugates and T-cell engager (TCE) molecules, featuring key opinion leaders with insights into ongoing research and clinical activities.
• The nomination of a candidate from the Trispecific TCE platform as part of the company's '5 by 5' R&D strategy.
• A comprehensive look at strategies for expansion into new therapeutic fields such as hematological cancers and autoimmune diseases, along with the progress of potential investigational new drug applications slated for 2026 and beyond.

About Zymeworks Inc.

Zymeworks is a global leader in the biotechnology sector, focused on the discovery, development, and commercialization of advanced biotherapeutics. Their mission centers around making a substantial impact on the lives of patients suffering from challenging cancers and other significant health issues. With a robust pipeline and an array of therapeutic platforms, Zymeworks operates a full-scale drug development engine that emphasizes precise engineering of antibody-based solutions.

Their significant achievements include the development of zanidatamab, a bispecific antibody targeting HER2, utilizing proprietary Azymetric™ technology. Zymeworks has forged partnerships with industry leaders like BeiGene, Ltd., and Jazz Pharmaceuticals to enhance development and commercialization efforts across various territories. Currently, zanidatamab is under evaluation in multiple clinical trials, demonstrating its potential as a leading treatment option for HER2-related cancers.

Investor and Media Contact Information

For those interested in learning more or attending the upcoming conferences and events, Zymeworks invites inquiries:

Investor Inquiries:

Shrinal Inamdar
Director, Investor Relations
(604) 678-1388
ir@zymeworks.com

Media Inquiries:

Diana Papove
Senior Director, Corporate Communications
(604) 678-1388
media@zymeworks.com

Frequently Asked Questions

1. What events is Zymeworks participating in?

Zymeworks will participate in several high-profile investor conferences and their own Research & Development Day.

2. When is the Research & Development Day?

The Research & Development Day is scheduled for December 12, 2024.

3. What is the significance of zanidatamab?

Zanidatamab is a bispecific antibody developed by Zymeworks targeting HER2 and is currently in clinical trials.

4. How can investors contact Zymeworks?

Investors can reach out to Shrinal Inamdar via email or phone for inquiries.

5. Where can I find more information about Zymeworks?

More information can be found on Zymeworks' official website.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.